<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5457">
  <stage>Registered</stage>
  <submitdate>15/08/2006</submitdate>
  <approvaldate>15/08/2006</approvaldate>
  <nctid>NCT00365001</nctid>
  <trial_identification>
    <studytitle>A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.</studytitle>
    <scientifictitle>A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>WP18663</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - tocilizumab [RoActemra/Actemra]
Treatment: drugs - Methotrexate
Treatment: drugs - Simvastatin

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: drugs: tocilizumab [RoActemra/Actemra]
10mg/kg iv on day 8

Treatment: drugs: Methotrexate
10-25mg po/week

Treatment: drugs: Simvastatin
40mg po on days 1, 15 and 43

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic parameters for simvastatin and metabolite, and methotrexate and metabolite.</outcome>
      <timepoint>Days 1, 15 and 43</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters for tocilizumab.</outcome>
      <timepoint>Days 11, 22, 29 and 36.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CRP, IL-6, sIL-6R changes</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AEs, laboratory parameters.</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, 18-75 years of age;

          -  rheumatoid arthritis for &gt;=6 months;

          -  methotrexate for &gt;=12 weeks prior to day 1 (stable at 10-25mg/week for 8 weeks).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  history of, or current inflammatory joint disease or rheumatic autoimmune disease
             other than RA;

          -  concurrent treatment with any DMARD other than methotrexate;

          -  prior treatment with tocilizumab.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 2 arm study will investigate the pharmacokinetics of simvastatin and methotrexate in
      combination with tocilizumab to assess any potential drug interactions. Patients will be
      randomized to receive either tocilizumab (10mg/kg iv infusion on day 8) + methotrexate
      (10-25mg po /week) or tocilizumab + methotrexate + simvastatin (40mg po on days 1, 15 and
      43). Blood samples will be taken for analysis at intervals up to day 44. The anticipated time
      on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00365001</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>